Compare Amphastar Pharmaceuticals Inc (AMPH) vs The Vita Coco Company Inc (COCO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Vita Coco (COCO) trades at $71.40, up 0.21% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with 37.4% gross margins and 26.32% ROE, though valuation metrics appear elevated with a P/E of 51.74. Recent Q1 2026 earnings beat expectations by 47%, while analysts maintain a 60% buy rating consensus with a $78 price target. The company is scheduled to report Q2 2026 results on July 23, 2026.

COCO presents growth potential driven by market leadership in coconut water and projected revenue expansion to $659M in 2026. However, premium valuation and competitive pressures in the beverage sector warrant caution. The stock's near-term catalyst will be Q2 earnings performance against the $0.56 EPS expectation, with technical support at $69 and resistance at $73.